After years of rigorous research and foundational progress, the inflammasome drug development field is reaching a critical inflection point. With long-awaited clinical data now beginning to emerge, momentum is building, and the landscape is evolving rapidly. NodThera has shared encouraging results in Parkinson’s disease and obesity, Ventus has initiated a Phase IIa clinical trial, and Ventyx is progressing a diversified pipeline of inflammasome-targeting assets. As the race for first-in-class success accelerates, the field stands on the cusp of transformative breakthroughs.